(Q44616568)

4 December 2017

2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus (English)

1 reference

4 December 2017

opportunistic infection

1 reference

based on heuristic

inferred from title

author name string

US Public Health Service (USPHS)

series ordinal

1

1 reference

PubMed ID

11742438

4 December 2017

Infectious Diseases Society of America (IDSA)

series ordinal

2

1 reference

PubMed ID

11742438

4 December 2017

USPHS/IDSA Prevention of Opportunistic Infections Working Group

series ordinal

3

1 reference

4 December 2017

1 November 2001

1 reference

4 December 2017

1 reference

4 December 2017

2

1 reference

4 December 2017

6

1 reference

4 December 2017

493-554

1 reference

Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group

4 December 2017

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Fluconazole-induced congenital anomalies in three infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis S

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Sexual transmission and the natural history of human herpesvirus 8 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Mucosal shedding of human herpesvirus 8 in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Possible Effectiveness of Clarithromycin and Rifabutin for Cryptosporidiosis Chemoprophylaxis in HIV Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

Increasing Probability of Mother-to-Child Transmission of HHV-8 with Increasing Maternal Antibody Titer for HHV-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FAQML-UABK-5LLB-E615

10.1310/AQML-UABK-5LLB-E615

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference

PubMed ID

11742438